Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CASP8D
MCID: CSP005
MIFTS: 58

Caspase 8 Deficiency (CASP8D)

Categories: Blood diseases, Genetic diseases, Immune diseases, Infectious diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Caspase 8 Deficiency

About this section

MalaCards integrated aliases for Caspase 8 Deficiency:

Name: Caspase 8 Deficiency 57 12 20
Autoimmune Lymphoproliferative Syndrome Type 2b 12 20 29 6 15 71
Caspase-8 Deficiency 20 73 39
Alps2b 57 12 20
Ceds 57 12 58
Autoimmune Lymphoproliferative Syndrome with Recurrent Viral Infections 12 58
Alps with Recurrent Viral Infections 12 58
Caspase 8 Deficiency Syndrome 12 58
Autoimmune Lymphoproliferative Syndrome, Type Iib; Alps2b 57
Autoimmune Lymphoproliferative Syndrome, Type Iib 57
Autoimmune Lymphoproliferative Syndrome Type Iib 12
Caspase Eight Deficiency State 12
Casp8d 73

Characteristics:

Orphanet epidemiological data:

58
autoimmune lymphoproliferative syndrome with recurrent viral infections
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Childhood;

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal recessive


HPO:

31
caspase 8 deficiency:
Inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Infectious diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare immunological diseases


External Ids:

Disease Ontology 12 DOID:0110116
OMIM® 57 607271
ICD10 32 D47.9
ICD10 via Orphanet 33 D47.9
UMLS via Orphanet 72 C1846545
Orphanet 58 ORPHA275517
MedGen 41 C1846545
UMLS 71 C1846545
Sources

Summaries for Caspase 8 Deficiency

About this section
UniProtKB/Swiss-Prot : 73 Caspase-8 deficiency: Disorder resembling autoimmune lymphoproliferative syndrome (ALPS). It is characterized by lymphadenopathy, splenomegaly, and defective CD95- induced apoptosis of peripheral blood lymphocytes (PBLs). It leads to defects in activation of T-lymphocytes, B-lymphocytes, and natural killer cells leading to immunodeficiency characterized by recurrent sinopulmonary and herpes simplex virus infections and poor responses to immunization.

MalaCards based summary : Caspase 8 Deficiency, also known as autoimmune lymphoproliferative syndrome type 2b, is related to lymphoproliferative syndrome and hypermobile ehlers-danlos syndrome. An important gene associated with Caspase 8 Deficiency is CASP8 (Caspase 8), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Pembrolizumab and Panobinostat have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are failure to thrive and splenomegaly

Disease Ontology : 12 An autoimmune lymphoproliferative syndrome that has material basis in homozygous mutation in the CASP8 gene on chromosome 2q33.

OMIM® : 57 Caspase 8 deficiency is a syndrome of lymphadenopathy and splenomegaly, marginal elevation of 'double-negative T cells' (DNT; T-cell receptor alpha/beta+, CD4-/CD8-), defective FAS-induced apoptosis, and defective T-, B-, and natural killer (NK)-cell activation, with recurrent bacterial and viral infections (summary by Madkaikar et al., 2011). (607271) (Updated 05-Mar-2021)

Wikipedia : 74 Caspase-8 deficiency (CEDS) is a very rare genetic disorder of the immune system. It is caused by... more...

Sources

Related Diseases for Caspase 8 Deficiency

About this section

Diseases related to Caspase 8 Deficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 33)
# Related Disease Score Top Affiliating Genes
1 lymphoproliferative syndrome 30.1 FASLG FAS FADD CASP8 CASP10
2 hypermobile ehlers-danlos syndrome 30.0 PLOD1 FKBP14 COL5A2 COL5A1
3 ehlers-danlos syndrome 30.0 PLOD1 FKBP14 COL5A2 COL5A1
4 autoimmune lymphoproliferative syndrome 28.5 TNFRSF1A RIPK3 RIPK1 PCSK1 MLKL FASLG
5 classic ehlers-danlos syndrome 11.0
6 zika virus congenital syndrome 10.3 RIPK3 RIPK1
7 tendinopathy 10.3 COL5A1 CASP8
8 cutaneous diphtheria 10.2 RIPK1 PCSK1
9 ehlers-danlos syndrome, classic type, 2 10.2 COL5A2 COL5A1
10 kyphoscoliotic ehlers-danlos syndrome 10.2 PLOD1 FKBP14
11 lymphocytic gastritis 10.2 FASLG FAS
12 pneumoconiosis 10.1 FASLG FAS CASP8
13 post-transplant lymphoproliferative disease 10.1 TNFRSF1A FADD CASP8
14 hypomelanosis of ito 10.1 PLOD1 COL5A1
15 dystrophinopathies 10.1 TNFRSF1A CASP8
16 silicosis 10.1 FASLG FAS CASP1
17 orthostatic intolerance 10.0 PLOD1 COL5A2 COL5A1
18 collagen disease 10.0 PLOD1 FKBP14 COL5A2 COL5A1
19 loeys-dietz syndrome 10.0 PLOD1 FKBP14 COL5A2 COL5A1
20 pulmonary hypertension 9.9
21 nk cell deficiency 9.9
22 skin disease 9.9
23 neuroblastoma 9.9
24 splenomegaly 9.9
25 cowpox 9.9 TNFRSF1A FAS CASP8 CASP1
26 hypersensitivity reaction type iv disease 9.9 RIPK3 FASLG FAS FADD CASP8 CASP10
27 t-cell lymphoblastic leukemia/lymphoma 9.9 TNFRSF1A FASLG FAS CASP8
28 lymphoma, non-hodgkin, familial 9.8 TNFRSF1A FAS CFLAR CASP8 CASP10
29 cardiomyopathy, familial hypertrophic, 1 9.8 TNFRSF1A FAS CASP8 CASP10 CASP1
30 colon adenocarcinoma 9.8 TNFRSF1A FASLG FAS CFLAR CASP8
31 viral hepatitis 9.8 TNFRSF1A FASLG FAS
32 cone-rod dystrophy 2 9.5 TNFRSF1A FASLG FAS FADD CFLAR CASP8
33 multiple sclerosis 9.4 TNFRSF1A FASLG CFLAR CASP8 CASP1

Graphical network of the top 20 diseases related to Caspase 8 Deficiency:



Diseases related to Caspase 8 Deficiency
Sources

Symptoms & Phenotypes for Caspase 8 Deficiency

About this section

Human phenotypes related to Caspase 8 Deficiency:

31 (show all 18)
# Description HPO Frequency HPO Source Accession
1 failure to thrive 31 very rare (1%) HP:0001508
2 splenomegaly 31 very rare (1%) HP:0001744
3 short stature 31 very rare (1%) HP:0004322
4 asthma 31 very rare (1%) HP:0002099
5 chronic diarrhea 31 very rare (1%) HP:0002028
6 eczema 31 very rare (1%) HP:0000964
7 pneumonia 31 very rare (1%) HP:0002090
8 lymphadenopathy 31 very rare (1%) HP:0002716
9 recurrent sinopulmonary infections 31 very rare (1%) HP:0005425
10 decreased circulating iga level 31 very rare (1%) HP:0002720
11 decreased circulating igg level 31 very rare (1%) HP:0004315
12 decreased circulating total igm 31 very rare (1%) HP:0002850
13 recurrent herpes 31 very rare (1%) HP:0005353
14 decreased t cell activation 31 very rare (1%) HP:0005419
15 decreased cd4:cd8 ratio 31 very rare (1%) HP:0033222
16 defective b cell activation 31 very rare (1%) HP:0005384
17 reduced cd95-induced lymphocyte apoptosis 31 very rare (1%) HP:0033278
18 complete or near-complete absence of specific antibody response to unconjugated pneumococcus vaccine 31 very rare (1%) HP:0410300

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Growth Other:
failure to thrive

Growth Height:
short stature

Skin Nails Hair Skin:
eczema

Immunology:
lymphadenopathy
recurrent sinopulmonary infections
defective b cell activation
herpes simplex virus infection, mucocutaneous
defective cd95-induced apoptosis of peripheral blood lymphocytes
more
Abdomen Spleen:
splenomegaly

Respiratory Airways:
asthma
reactive airway disease

Respiratory Lung:
pneumonia

Abdomen Gastrointestinal:
diarrhea, chronic

Clinical features from OMIM®:

607271 (Updated 05-Mar-2021)

GenomeRNAi Phenotypes related to Caspase 8 Deficiency according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.81 CASP1 CASP8
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.81 CASP1 CASP8 FADD FAS FASLG TNFRSF1A
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.81 CASP8
4 Reduced mammosphere formation GR00396-S 9.5 CASP1 COL5A1 COL5A2 FADD FAS FASLG
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CFLAR FADD FAS RIPK1 TNFRSF1A
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 CASP1 CFLAR FADD FAS RIPK1 TNFRSF1A
7 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.4 CASP8

MGI Mouse Phenotypes related to Caspase 8 Deficiency:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.29 CASP1 CASP8 CFLAR COL5A1 COL5A2 FADD
2 cellular MP:0005384 10.27 CASP1 CASP8 CFLAR CYLD FADD FAS
3 growth/size/body region MP:0005378 10.25 CASP1 CASP8 CFLAR COL5A1 COL5A2 CYLD
4 hematopoietic system MP:0005397 10.22 CASP1 CASP8 CFLAR CYLD FADD FAS
5 endocrine/exocrine gland MP:0005379 10.2 CASP1 CASP8 CFLAR CYLD FADD FAS
6 homeostasis/metabolism MP:0005376 10.18 CASP1 CASP8 CFLAR CYLD FADD FAS
7 digestive/alimentary MP:0005381 10.13 CASP1 CYLD FADD FAS FASLG PCSK1
8 immune system MP:0005387 10.13 CASP1 CASP8 CFLAR CYLD FADD FAS
9 integument MP:0010771 10 CASP1 CASP8 COL5A1 COL5A2 CYLD FAS
10 mortality/aging MP:0010768 9.86 CASP1 CASP8 CFLAR COL5A1 COL5A2 CYLD
11 liver/biliary system MP:0005370 9.7 CASP8 FADD FAS FASLG RIPK1 RIPK3
12 neoplasm MP:0002006 9.1 CASP1 CASP8 CYLD FAS FASLG TNFRSF1A
Sources

Drugs & Therapeutics for Caspase 8 Deficiency

About this section

Drugs for Caspase 8 Deficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pembrolizumab Approved Phase 2 1374853-91-4
2
Panobinostat Approved, Investigational Phase 1, Phase 2 404950-80-7 6918837
3 Antirheumatic Agents Phase 2
4 Adjuvants, Immunologic Phase 2
5 Interleukin-4 Phase 2
6 Antineoplastic Agents, Immunological Phase 2
7 Histone Deacetylase Inhibitors Phase 1, Phase 2
8
Temozolomide Approved, Investigational Phase 1 85622-93-1 5394
9
Iodine Approved, Investigational Phase 1 7553-56-2 807
10
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
11
Edetic Acid Approved, Vet_approved Phase 1 60-00-4, 62-33-9 6049
12
Pentetic acid Approved Phase 1 67-43-6
13
Cadexomer iodine Experimental Phase 1 94820-09-4
14 Alkylating Agents Phase 1
15 Anesthetics Phase 1
16 Immunoglobulins Phase 1
17 Antibodies Phase 1
18 topoisomerase I inhibitors Phase 1
19 Immunologic Factors Phase 1
20 Antibodies, Monoclonal Phase 1
21 Calamus Phase 1
22 Vaccines Phase 1
23 Pharmaceutical Solutions Phase 1
24
Diethylenetriamine Phase 1 111-40-0 8111
25
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
26
tannic acid Approved 1401-55-4
27
Infliximab Approved 170277-31-3
28 Dermatologic Agents
29 Gastrointestinal Agents

Interventional clinical trials:

(show all 21)
# Name Status NCT ID Phase Drugs
1 An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma Completed NCT02858895 Phase 2 MDNA55
2 A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal (GDNF) Infusions Administered Via Convection Enhanced Delivery (CED) in Subjects With Parkinson&Apos;s Disease Completed NCT03652363 Phase 2 glial cell line-derived neurotrophic factor
3 A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of PVSRIPO and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma Recruiting NCT04479241 Phase 2
4 An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-enhanced Delivery (CED) in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated With External Beam Radiation Therapy Active, not recruiting NCT03566199 Phase 1, Phase 2 Panobinostat Nanoparticle Formulation MTX110;Convection-Enhanced Delivery (CED)
5 Phase II, Multi-center, Open-Label, Single-Arm Study of Intratumoral Infusion of PRX321 in Subjects With Glioblastoma Multiforme at First Recurrence or Progression Withdrawn NCT00797940 Phase 2 IL-4PE
6 Phase I Study of Convection Enhanced Delivery (CED) of IL13-PE38QQR Infusion After Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma Completed NCT00089427 Phase 1 IL13-PE38QQR;Temozolomide with radiation therapy
7 A Phase I Study Examining the Feasibility of Intermittent Convection-Enhanced Delivery (CED) of MTX110 for the Treatment of Children With Newly Diagnosed Diffuse Midline Gliomas Recruiting NCT04264143 Phase 1 Infusate with MTX110 and gadolinium
8 A Phase I Study of Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy Recruiting NCT01502917 Phase 1 Radioactive iodine-labeled monoclonal antibody omburtamab
9 A Phase I and Early Efficacy Study of Convection Enhanced Delivery of Irinotecan Liposome Injection Using Real Time Imaging With Gadolinium in Children With Diffuse Intrinsic Pontine Glioma Recruiting NCT03086616 Phase 1 Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
10 Phase Ib Study of Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Malignant Glioma in Children Recruiting NCT03043391 Phase 1
11 A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease Active, not recruiting NCT01621581 Phase 1
12 A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via Convection-Enhanced Delivery In Patients With Progressive And/Or Multiple Recurrent Glioblastoma Multiforme Active, not recruiting NCT02869243 Phase 1 hrBMP4
13 A Phase I Trial of Carboplatin Administered by Convection-Enhanced Delivery to Patients With Recurrent/Progressive Glioblastoma Multiforme Withdrawn NCT01317212 Phase 1 Peritumoural carboplatin administration.
14 Verbessertes Therapiemanagement für pädiatrische CED-Patienten Mit Chronisch-entzündlicher Darmerkrankung: Eine Randomisierte Multizentrische Studie, Welche Die Effektivität Einer Talspiegel-gesteuerten Infliximab-Erhaltungsphase Mit Dem herkömmlichen Dosierungsregime Vergleicht Trough Level Optimized Pediatric Inflammatory Bowel Disease Therapy: A Randomized Multicenter Study Comparing Effectiveness of Trough Level Optimized Infliximab Maintenance Therapy With Standard Dosing Regimen of Pediatric Patients With Crohn's Disease Unknown status NCT02522169 Infliximab
15 Assessment of Duodenal Epithelial Integrity in Celiac Disease With Mucosal Impedance Completed NCT03152279
16 A Pilot Trial of Intraparenchymally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Requiring Stereotactic Biopsy Completed NCT02278510 Early Phase 1 Topotecan;Gadolinium DTPA
17 Kids + Adolescents Research Learning On Tablet Teaching Aachen Recruiting NCT03833778
18 A Study of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy Recruiting NCT03927274 Early Phase 1 Topotecan
19 Expanded Access Protocol for the Treatment of Glioblastoma With PVSRIPO Available NCT04599647
20 A Pilot Trial of Intraparenchymally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Undergoing A Clinically-Indicated Surgical Resection (IND 117,240) Terminated NCT02500459 Early Phase 1 topotecan
21 Pilot Trial of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy (IND 117,240) Withdrawn NCT03193463 Early Phase 1 Topotecan (<=8cc);Topotecan (>8cc);Lower Does Topotecan

Search NIH Clinical Center for Caspase 8 Deficiency

Sources

Genetic Tests for Caspase 8 Deficiency

About this section

Genetic tests related to Caspase 8 Deficiency:

# Genetic test Affiliating Genes
1 Autoimmune Lymphoproliferative Syndrome Type 2b 29 CASP8
Sources

Anatomical Context for Caspase 8 Deficiency

About this section

MalaCards organs/tissues related to Caspase 8 Deficiency:

40
T Cells, Bone, Bone Marrow, Thyroid, Skin
Sources

Publications for Caspase 8 Deficiency

About this section

Articles related to Caspase 8 Deficiency:

(show all 37)
# Title Authors PMID Year
1
Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. 57 6 61
12353035 2002
2
Advances in autoimmune lymphoproliferative syndromes. 57
21447005 2011
3
Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). 57
19930184 2010
4
Somatic mutations--not just for cancer anymore. 57
15459299 2004
5
Smac mimetics can provoke lytic cell death that is neither apoptotic nor necroptotic. 61
32440848 2020
6
FADD and Caspase-8 Regulate Gut Homeostasis and Inflammation by Controlling MLKL- and GSDMD-Mediated Death of Intestinal Epithelial Cells. 61
32362323 2020
7
Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. 61
31748744 2019
8
Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis. 61
31511692 2019
9
Redundant and receptor-specific activities of TRADD, RIPK1 and FADD in death receptor signaling. 61
30741924 2019
10
Intestinal Inflammation and Dysregulated Immunity in Patients With Inherited Caspase-8 Deficiency. 61
30267714 2019
11
Caspase-8 deficiency in mouse embryos triggers chronic RIPK1-dependent activation of inflammatory genes, independently of RIPK3. 61
29666472 2018
12
The caspase-8/RIPK3 signaling axis in antigen presenting cells controls the inflammatory arthritic response. 61
28978351 2017
13
Dynamic quantitative proteomics characterization of TNF-α-induced necroptosis. 61
27704275 2016
14
Conditional deletion of caspase-8 in macrophages alters macrophage activation in a RIPK-dependent manner. 61
26471282 2015
15
Caspase-8 Deficiency Presenting as Late-Onset Multi-Organ Lymphocytic Infiltration with Granulomas in two Adult Siblings. 61
25814141 2015
16
Caspase-8 acts as a molecular rheostat to limit RIPK1- and MyD88-mediated dendritic cell activation. 61
24808358 2014
17
Cellular FLICE-like inhibitory protein secures intestinal epithelial cell survival and immune homeostasis by regulating caspase-8. 61
24036366 2013
18
Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. 61
23536557 2013
19
Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. 61
23260196 2013
20
Mechanisms of necroptosis in T cells. 61
21402742 2011
21
Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease. 61
19720838 2009
22
Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis. 61
19190106 2009
23
The technological transformation of patient-driven human immunology research. 61
18818883 2009
24
A role for cFLIP in B cell proliferation and stress MAPK regulation. 61
19109151 2009
25
Caspase-8 deficiency facilitates cellular transformation in vitro. 61
18566604 2008
26
Genetic defects of apoptosis and primary immunodeficiency. 61
18424336 2008
27
Bid truncation mediated by caspases-3 and -9 in vinorelbine-induced apoptosis. 61
18297401 2008
28
Role of caspase-8 in hepatocyte response to infection and injury in mice. 61
17385212 2007
29
Partial correction of abnormal cardiac development in caspase-8-deficient mice by cardiomyocyte expression of p 35. 61
16245150 2005
30
Caspase-8 deficiency in T cells leads to a lethal lymphoinfiltrative immune disorder. 61
16157684 2005
31
Volatile anesthetics induce caspase-dependent, mitochondria-mediated apoptosis in human T lymphocytes in vitro. 61
15915027 2005
32
Requirement for caspase-8 in NF-kappaB activation by antigen receptor. 61
15746428 2005
33
Immune disorders caused by defects in the caspase cascade. 61
12906772 2003
34
Targeting the tumor necrosis factor-related apoptosis-inducing ligand path in neuroblastoma. 61
12880973 2003
35
ASC is an activating adaptor for NF-kappa B and caspase-8-dependent apoptosis. 61
12646168 2003
36
Basic and clinical immunology. 61
12618748 2003
37
ER stress induces caspase-8 activation, stimulating cytochrome c release and caspase-9 activation. 61
12581736 2003
Sources

Variations for Caspase 8 Deficiency

About this section

ClinVar genetic disease variations for Caspase 8 Deficiency:

6 (show top 50) (show all 102)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CASP8 NM_001372051.1(CASP8):c.742C>T (p.Arg248Trp) SNV Pathogenic 7760 rs17860424 2:202141631-202141631 2:201276908-201276908
2 CASP10 NC_000002.12:g.(?_201228913)_(201286614_?)del Deletion Pathogenic 659600 2:202093636-202151337 2:201228913-201286614
3 CASP8 NM_001372051.1(CASP8):c.202C>T (p.Arg68Ter) SNV Pathogenic 946113 2:202131411-202131411 2:201266688-201266688
4 CASP8 NM_001372051.1(CASP8):c.306-1949_306-1947delinsC Indel Pathogenic 968654 2:202134290-202134292 2:201269567-201269569
5 CASP8 NM_001372051.1(CASP8):c.1303C>T (p.Arg435Ter) SNV Pathogenic 973624 2:202150039-202150039 2:201285316-201285316
6 CASP8 NC_000002.12:g.(?_201276807)_(201276988_?)dup Duplication Likely pathogenic 830621 2:202141530-202141711
7 CASP8 NM_001372051.1(CASP8):c.892A>G (p.Ile298Val) SNV Conflicting interpretations of pathogenicity 533732 rs146286958 2:202149628-202149628 2:201284905-201284905
8 CASP8 NM_001372051.1(CASP8):c.286G>T (p.Ala96Ser) SNV Uncertain significance 571008 rs762297913 2:202131495-202131495 2:201266772-201266772
9 CASP8 NM_001228.4(CASP8):c.341A>G (p.Asn114Ser) SNV Uncertain significance 573566 rs1559354162 2:202134268-202134268 2:201269545-201269545
10 CASP8 NM_001372051.1(CASP8):c.1103G>C (p.Gly368Ala) SNV Uncertain significance 576198 rs758525204 2:202149839-202149839 2:201285116-201285116
11 CASP8 NM_001372051.1(CASP8):c.159G>A (p.Met53Ile) SNV Uncertain significance 625904 rs200261147 2:202131368-202131368 2:201266645-201266645
12 CASP8 NM_001372051.1(CASP8):c.1165C>T (p.Gln389Ter) SNV Uncertain significance 631840 rs747862347 2:202149901-202149901 2:201285178-201285178
13 CASP8 NM_001372051.1(CASP8):c.761T>G (p.Leu254Arg) SNV Uncertain significance 639795 rs1576347035 2:202141650-202141650 2:201276927-201276927
14 CASP8 NM_001372051.1(CASP8):c.701G>A (p.Gly234Glu) SNV Uncertain significance 642198 rs1390728717 2:202141590-202141590 2:201276867-201276867
15 CASP8 NM_001372051.1(CASP8):c.1310A>T (p.Asp437Val) SNV Uncertain significance 648682 rs561729612 2:202151187-202151187 2:201286464-201286464
16 CASP8 NM_001372051.1(CASP8):c.802+4C>A SNV Uncertain significance 653865 rs746813867 2:202141695-202141695 2:201276972-201276972
17 CASP8 NM_001372051.1(CASP8):c.778A>G (p.Arg260Gly) SNV Uncertain significance 654340 rs1350639573 2:202141667-202141667 2:201276944-201276944
18 CASP8 NM_001372051.1(CASP8):c.*304C>T SNV Uncertain significance 333516 rs886055433 2:202151621-202151621 2:201286898-201286898
19 CASP8 NM_001372051.1(CASP8):c.443A>G (p.Lys148Arg) SNV Uncertain significance 333500 rs148697064 2:202137392-202137392 2:201272669-201272669
20 CASP8 NM_001372051.1(CASP8):c.843C>A (p.Ile281=) SNV Uncertain significance 333503 rs199934929 2:202149579-202149579 2:201284856-201284856
21 CASP8 NM_001372051.1(CASP8):c.432A>G (p.Ile144Met) SNV Uncertain significance 333499 rs149933993 2:202137381-202137381 2:201272658-201272658
22 CASP8 NM_001372051.1(CASP8):c.*591T>C SNV Uncertain significance 333522 rs187758494 2:202151908-202151908 2:201287185-201287185
23 CASP8 NM_001372051.1(CASP8):c.*98C>T SNV Uncertain significance 333511 rs36155452 2:202151415-202151415 2:201286692-201286692
24 CASP8 NM_001372051.1(CASP8):c.1308C>T (p.Gly436=) SNV Uncertain significance 333508 rs777463099 2:202151185-202151185 2:201286462-201286462
25 CASP8 NM_001372051.1(CASP8):c.*316C>T SNV Uncertain significance 333517 rs35419671 2:202151633-202151633 2:201286910-201286910
26 CASP8 NM_001372051.1(CASP8):c.*124C>T SNV Uncertain significance 333514 rs886055432 2:202151441-202151441 2:201286718-201286718
27 CASP8 NM_001372051.1(CASP8):c.1038T>C (p.Pro346=) SNV Uncertain significance 333506 rs768360449 2:202149774-202149774 2:201285051-201285051
28 CASP8 NM_001228.4(CASP8):c.711+6C>T SNV Uncertain significance 333501 rs370400442 2:202139682-202139682 2:201274959-201274959
29 CASP8 NM_001372051.1(CASP8):c.*578C>A SNV Uncertain significance 333521 rs886055434 2:202151895-202151895 2:201287172-201287172
30 CASP8 NM_001372051.1(CASP8):c.*812T>A SNV Uncertain significance 333524 rs538987233 2:202152129-202152129 2:201287406-201287406
31 CASP8 NM_001228.4(CASP8):c.1355+12C>T SNV Uncertain significance 333507 rs375465590 2:202150052-202150052 2:201285329-201285329
32 CASP8 NM_001372051.1(CASP8):c.919A>G (p.Met307Val) SNV Uncertain significance 333504 rs148960588 2:202149655-202149655 2:201284932-201284932
33 CASP8 NM_001372051.1(CASP8):c.815C>G (p.Thr272Arg) SNV Uncertain significance 841249 2:202149551-202149551 2:201284828-201284828
34 CASP8 NM_001372051.1(CASP8):c.775G>A (p.Asp259Asn) SNV Uncertain significance 845577 2:202141664-202141664 2:201276941-201276941
35 CASP8 NM_001372051.1(CASP8):c.306-1954C>G SNV Uncertain significance 853291 2:202134285-202134285 2:201269562-201269562
36 CASP8 NM_001372051.1(CASP8):c.415C>A (p.Leu139Met) SNV Uncertain significance 856194 2:202137364-202137364 2:201272641-201272641
37 CASP8 NM_001372051.1(CASP8):c.896A>C (p.Tyr299Ser) SNV Uncertain significance 863460 2:202149632-202149632 2:201284909-201284909
38 CASP8 NM_001372051.1(CASP8):c.306-1980C>A SNV Uncertain significance 895689 2:202134259-202134259 2:201269536-201269536
39 CASP8 NM_001372051.1(CASP8):c.452T>C (p.Ile151Thr) SNV Uncertain significance 895690 2:202137401-202137401 2:201272678-201272678
40 CASP8 NM_001372051.1(CASP8):c.469T>C (p.Leu157=) SNV Uncertain significance 895691 2:202137418-202137418 2:201272695-201272695
41 CASP8 NM_001372051.1(CASP8):c.528C>T (p.Asn176=) SNV Uncertain significance 895692 2:202137477-202137477 2:201272754-201272754
42 CASP8 NM_001372051.1(CASP8):c.*194T>A SNV Uncertain significance 895768 2:202151511-202151511 2:201286788-201286788
43 CASP8 NM_001372051.1(CASP8):c.*223C>T SNV Uncertain significance 895769 2:202151540-202151540 2:201286817-201286817
44 CASP8 NM_001372051.1(CASP8):c.*266C>G SNV Uncertain significance 895770 2:202151583-202151583 2:201286860-201286860
45 CASP8 NM_001372051.1(CASP8):c.*272A>G SNV Uncertain significance 895771 2:202151589-202151589 2:201286866-201286866
46 CASP8 NM_001372051.1(CASP8):c.*314C>T SNV Uncertain significance 895772 2:202151631-202151631 2:201286908-201286908
47 CASP8 NM_001372051.1(CASP8):c.603G>C (p.Glu201Asp) SNV Uncertain significance 895972 2:202139619-202139619 2:201274896-201274896
48 CASP8 NM_001372051.1(CASP8):c.698G>A (p.Arg233Gln) SNV Uncertain significance 895973 2:202141587-202141587 2:201276864-201276864
49 CASP8 NM_001372051.1(CASP8):c.*346C>T SNV Uncertain significance 896050 2:202151663-202151663 2:201286940-201286940
50 CASP8 NM_001372051.1(CASP8):c.*686C>T SNV Uncertain significance 896051 2:202152003-202152003 2:201287280-201287280

UniProtKB/Swiss-Prot genetic disease variations for Caspase 8 Deficiency:

73
# Symbol AA change Variation ID SNP ID
1 CASP8 p.Arg248Trp VAR_014204 rs17860424

Sources

Expression for Caspase 8 Deficiency

About this section
Search GEO for disease gene expression data for Caspase 8 Deficiency.
Sources

Pathways for Caspase 8 Deficiency

About this section

Pathways related to Caspase 8 Deficiency according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Apoptotic Pathways in Synovial Fibroblasts 63
Show member pathways
 13.8 TNFRSF1A RIPK1 FASLG FAS FADD CFLAR
2
ERK Signaling 63
Show member pathways
 13.79 TNFRSF1A RIPK1 FASLG FAS FADD COL5A2
3
TNFR1 Pathway 63
Show member pathways
 13.09 TNFRSF1A RIPK3 RIPK1 FASLG FAS FADD
4
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.08 TNFRSF1A RIPK1 FASLG FAS FADD CYLD
5
Human cytomegalovirus infection 36
Show member pathways
 12.92 TNFRSF1A RIPK1 FASLG FAS FADD CASP8
6
Measles 36
Show member pathways
 12.82 TNFRSF1A RIPK1 FASLG FAS FADD CASP8
7
Allograft rejection 36 1
Show member pathways
 12.81 FASLG FAS FADD COL5A1 CASP8
8
Herpes simplex virus 1 infection 36
12.76 TNFRSF1A FASLG FAS FADD CASP8
9
Salmonella infection (KEGG) 36
Show member pathways
 12.76 TNFRSF1A RIPK3 RIPK1 MLKL FASLG FAS
10
Chks in Checkpoint Regulation 63
Show member pathways
 12.73 RIPK1 FASLG FAS FADD CFLAR CASP8
11
MAPK signaling pathway 36 1
12.72 TNFRSF1A FASLG FAS CASP8 CASP1
12
Apoptosis Modulation and Signaling 1
Show member pathways
 12.71 TNFRSF1A RIPK1 FASLG FAS FADD CFLAR
13
nNOS Signaling in Skeletal Muscle 63
Show member pathways
 12.69 TNFRSF1A FASLG FAS FADD CASP8 CASP10
14
TRAF Pathway 63
Show member pathways
 12.61 TNFRSF1A RIPK1 FASLG FAS FADD CASP8
15
NF-kappaB Signaling 4
12.58 TNFRSF1A RIPK3 RIPK1 FASLG FAS CYLD
16
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 65
Show member pathways
 12.52 RIPK1 FADD CYLD CASP8 CASP10
17
TNF signaling 65
Show member pathways
 12.35 TNFRSF1A RIPK1 FASLG FAS FADD CYLD
18
Dimerization of procaspase-8 65
Show member pathways
 12.28 RIPK3 RIPK1 MLKL FASLG FAS FADD
19
p53 Signaling 63
Show member pathways
 12.27 FASLG FAS CASP8 CASP10 CASP1
20
NOD-like receptor signaling pathway 36
12.25 RIPK3 RIPK1 FADD CASP8 CASP1
21
Tuberculosis 36
12.21 TNFRSF1A FADD CASP8 CASP10
22
Apoptosis and survival Caspase cascade 23
Show member pathways
 12.17 TNFRSF1A RIPK1 FASLG FAS FADD CFLAR
23
Alzheimers Disease 1
12.11 TNFRSF1A FAS FADD CASP8
24
Ceramide Pathway 63
Show member pathways
 12.06 TNFRSF1A RIPK1 FADD CASP8 CASP10 CASP1
25
NF-kappa B signaling pathway 36
11.93 TNFRSF1A RIPK1 CYLD CFLAR
26
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways 65
Show member pathways
 11.92 CYLD CASP8 CASP1
27
Apoptosis and Autophagy 4
11.92 TNFRSF1A RIPK3 RIPK1 MLKL FASLG FAS
28
TNF signaling pathway 36
11.9 TNFRSF1A RIPK3 RIPK1 PGAM5 MLKL FAS
29
TP53 Regulates Transcription of Cell Death Genes 65
Show member pathways
 11.88 FAS CASP10 CASP1
30
Nanomaterial induced apoptosis 1
Show member pathways
 11.87 TNFRSF1A RIPK1 FASLG FAS FADD CFLAR
31
Platinum drug resistance 36
11.77 FASLG FAS FADD CASP8
32
TNF Superfamily Pathway: Human Ligand-Receptor Interactions and their Associated Functions 64
Show member pathways
 11.76 TNFRSF1A FASLG FAS
33
Necroptosis 36
Show member pathways
 11.63 TNFRSF1A RIPK3 RIPK1 PGAM5 MLKL FASLG
34
Photodynamic therapy-induced AP-1 survival signaling. 1
11.58 TNFRSF1A FASLG FAS CFLAR
35
Ceramide signaling pathway 1
11.5 TNFRSF1A RIPK1 FADD CASP8
36
all-trans-Retinoic Acid Mediated Apoptosis 63
11.49 FADD CFLAR CASP8
37
Signal transduction_JNK pathway 23
11.46 TNFRSF1A FASLG FAS
38
Apoptosis and survival_Regulation of Apoptosis by Mitochondrial Proteins 23
Show member pathways
 11.39 TNFRSF1A FAS CASP8
39
IL-15 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types 64
Show member pathways
 11.35 TNFRSF1A FASLG FAS
Sources

GO Terms for Caspase 8 Deficiency

About this section

Cellular components related to Caspase 8 Deficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.8 TNFRSF1A RIPK1 FASLG FAS FADD CFLAR
2 death-inducing signaling complex GO:0031264 9.55 RIPK1 FAS FADD CFLAR CASP8
3 ripoptosome GO:0097342 9.35 RIPK1 FADD CFLAR CASP8 CASP10
4 collagen type V trimer GO:0005588 9.32 COL5A2 COL5A1
5 CD95 death-inducing signaling complex GO:0031265 9.02 FAS FADD CFLAR CASP8 CASP10

Biological processes related to Caspase 8 Deficiency according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 10.13 TNFRSF1A RIPK3 RIPK1 FASLG FAS FADD
2 proteolysis GO:0006508 10.12 PCSK1 CYLD CFLAR CASP8 CASP10 CASP1
3 viral process GO:0016032 10.08 TNFRSF1A RIPK1 FADD CFLAR CASP8
4 positive regulation of apoptotic process GO:0043065 10.05 RIPK1 FASLG FAS FADD CASP8
5 regulation of apoptotic process GO:0042981 10.05 RIPK3 FAS FADD CFLAR CASP8 CASP10
6 cell surface receptor signaling pathway GO:0007166 10.04 TNFRSF1A MLKL FADD CASP8 CASP10
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.01 TNFRSF1A RIPK1 FASLG FADD CFLAR CASP8
8 tumor necrosis factor-mediated signaling pathway GO:0033209 9.93 TNFRSF1A RIPK1 FASLG FAS
9 cellular response to mechanical stimulus GO:0071260 9.93 TNFRSF1A FAS FADD CASP8 CASP1
10 extrinsic apoptotic signaling pathway GO:0097191 9.89 RIPK1 FASLG FAS FADD CASP8
11 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.87 TNFRSF1A FASLG FADD CASP8
12 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.86 TNFRSF1A RIPK1 CYLD CASP8
13 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.86 RIPK1 FASLG FAS FADD CFLAR CASP8
14 execution phase of apoptosis GO:0097194 9.85 CFLAR CASP8 CASP10 CASP1
15 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.85 RIPK1 FASLG FAS FADD CFLAR CASP8
16 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.84 TNFRSF1A RIPK3 RIPK1
17 programmed cell death GO:0012501 9.83 RIPK3 RIPK1 PGAM5 MLKL
18 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.8 RIPK1 FADD CASP8
19 necroptotic process GO:0070266 9.8 RIPK3 RIPK1 PGAM5 MLKL FASLG CYLD
20 positive regulation of extrinsic apoptotic signaling pathway GO:2001238 9.79 RIPK1 FADD CYLD
21 death-inducing signaling complex assembly GO:0071550 9.78 TNFRSF1A RIPK1 FADD CASP8
22 negative regulation of necroptotic process GO:0060546 9.77 RIPK1 FADD CASP8
23 positive regulation of macrophage differentiation GO:0045651 9.77 RIPK1 FADD CASP8
24 toll-like receptor 3 signaling pathway GO:0034138 9.76 RIPK1 FADD CASP8
25 regulation of necroptotic process GO:0060544 9.76 FADD CYLD CFLAR CASP8
26 programmed necrotic cell death GO:0097300 9.75 RIPK3 RIPK1 CASP1
27 positive regulation of proteolysis GO:0045862 9.69 FADD CASP8
28 pyroptosis GO:0070269 9.69 CASP8 CASP1
29 lymph node development GO:0048535 9.68 RIPK3 FADD
30 activation of cysteine-type endopeptidase activity GO:0097202 9.68 FADD CASP8
31 positive regulation of necrotic cell death GO:0010940 9.68 RIPK3 RIPK1
32 amyloid fibril formation GO:1990000 9.67 RIPK3 RIPK1
33 activation of JNKK activity GO:0007256 9.67 RIPK1 MLKL
34 positive regulation of necroptotic process GO:0060545 9.66 RIPK3 RIPK1
35 T cell apoptotic process GO:0070231 9.66 RIPK1 FASLG
36 TRAIL-activated apoptotic signaling pathway GO:0036462 9.65 FADD CASP8
37 motor neuron apoptotic process GO:0097049 9.64 FAS FADD
38 eye morphogenesis GO:0048592 9.63 COL5A2 COL5A1
39 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.63 RIPK1 FASLG FAS FADD CFLAR CASP8
40 negative regulation of endodermal cell differentiation GO:1903225 9.61 COL5A2 COL5A1
41 execution phase of necroptosis GO:0097528 9.61 RIPK3 MLKL
42 necroptotic signaling pathway GO:0097527 9.43 RIPK3 RIPK1 MLKL FASLG FAS FADD
43 apoptotic signaling pathway GO:0097190 9.28 RIPK3 RIPK1 FASLG FAS FADD CFLAR

Molecular functions related to Caspase 8 Deficiency according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.11 TNFRSF1A RIPK3 RIPK1 PCSK1 MLKL FAS
2 peptidase activity GO:0008233 9.92 PCSK1 CYLD CASP8 CASP10 CASP1
3 protein-containing complex binding GO:0044877 9.91 RIPK3 RIPK1 PGAM5 MLKL FADD CFLAR
4 cysteine-type peptidase activity GO:0008234 9.8 CYLD CFLAR CASP8 CASP10 CASP1
5 cysteine-type endopeptidase activity GO:0004197 9.73 CFLAR CASP8 CASP10 CASP1
6 tumor necrosis factor receptor binding GO:0005164 9.65 FASLG FADD CASP8
7 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.56 CFLAR CASP8 CASP10 CASP1
8 tumor necrosis factor-activated receptor activity GO:0005031 9.51 TNFRSF1A FAS
9 death effector domain binding GO:0035877 9.5 FADD CASP8 CASP10
10 JUN kinase kinase kinase activity GO:0004706 9.49 RIPK1 MLKL
11 cysteine-type endopeptidase activity involved in execution phase of apoptosis GO:0097200 9.46 CFLAR CASP8 CASP10 CASP1
12 cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097199 9.26 CFLAR CASP8 CASP10 CASP1
13 death receptor binding GO:0005123 9.02 RIPK1 FASLG FADD CFLAR CASP8
Sources

Sources for Caspase 8 Deficiency

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....